tert-butyl 7-(2-adamantylcarbamoyl)-1,7-diazaspiro[4.4]nonane-1-carboxylate | 1192755-92-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂螺环衍生物
• 英文名称: tert-butyl 7-(2-adamantylcarbamoyl)-1,7-diazaspiro[4.4]nonane-1-carboxylate
• CAS: 1192755-92-2
• 化学式: C₂₃H₃₇N₃O₃
• 分子量: 403.565
• InChiKey: LLWKZPQBBDZMND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  61.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1,7-二氮杂螺[4.4]壬烷-1-羧酸 1,1-二甲基乙酯 、 2-氨基金刚烷 、 N,N'-羰基二咪唑 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以89%的产率得到tert-butyl 7-(2-adamantylcarbamoyl)-1,7-diazaspiro[4.4]nonane-1-carboxylate
  参考文献：
  名称：

  [EN] CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1
  [FR] INHIBITEURS DE LA 11-BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE 1 À BASE DE CARBAMATE ET D'URÉE

  摘要：

  公开号：

  WO2009131669A3

文献信息

• Carbamate And Urea Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1
  申请人：Claremon David A.

  公开号：US20110112062A1

  公开（公告）日：2011-05-12

  This invention relates to novel compounds of the Formula I, II, III, IHa, NIb, IV, IVa, IVb, IVc, IVd, IVe, V, Va, Vb1 V1, V1a, VIb, VII, Vi1a, VIIb, VIII, V111a, VIIIb, IX, IXa, X, and Xa, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.

  本发明涉及公式 I、II、III、IHa、NIb、IV、IVa、IVb、IVc、IVd、IVe、V、Va、Vb1、V1、V1a、VIb、VII、Vi1a、VIIb、VIII、V111a、VIIIb、IX、IXa、X 和 Xa 的新化合物，其药学上可接受的盐以及其制备的药物组合物，用于治疗与哺乳动物中 11 β-HSD1 调节或抑制相关的疾病。本发明还涉及所述新化合物的药物组合物和在细胞中减少或控制皮质醇的产生或抑制皮质酮转化为皮质醇的方法。
• Carbamate and urea inhibitors of 11Beta-hydroxysteroid dehydrogenase 1
  申请人：Claremon David A.

  公开号：US08399504B2

  公开（公告）日：2013-03-19

  This invention relates to novel compounds of the Formula (I) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds of the Formula (I) and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

  本发明涉及公式(I)的新化合物，其药学上可接受的盐和制药组合物，用于治疗与哺乳动物中11β-HSD1的调节或抑制相关的疾病。本发明还涉及公式(I)的新化合物的制药组合物和它们在细胞中减少或控制皮质醇的产生或抑制皮质酮转化为皮质醇的方法。
• Carbamate and urea inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
  申请人：Claremon David A.

  公开号：US08828985B2

  公开（公告）日：2014-09-09

  This invention relates to novel compounds of the Formula (I) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds of the Formula (I) and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

  本发明涉及公式（I）的新化合物及其药学上可接受的盐和制药组合物，这些化合物对于治疗与哺乳动物中11β-HSD1的调节或抑制有关的疾病是有用的。本发明还涉及公式（I）的新化合物的制药组合物以及它们在细胞中减少或控制皮质醇的产生或抑制皮质酮转化为皮质醇的方法。
• CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1
  申请人：Claremon David A.

  公开号：US20130244994A1

  公开（公告）日：2013-09-19

  This invention relates to novel compounds of the Formula (I) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds of the Formula (I) and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

  本发明涉及公式(I)的新化合物及其药学上可接受的盐和药物组合物，用于治疗与哺乳动物中11β-HSD1的调节或抑制有关的疾病。本发明还涉及公式(I)的新化合物的药物组合物以及它们在细胞中减少或控制皮质醇的产生或抑制皮质酮转化为皮质醇的方法的使用。
• US8399504B2
  申请人：——

  公开号：US8399504B2

  公开（公告）日：2013-03-19